Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with liver cancer (called HCC) through medical imaging, and who are receiving or are planned to receive treatment.
- People who are being treated (or will be treated) with a procedure called TARE, which involves delivering tiny radioactive beads through the blood vessels to the liver.
- People who had medical imaging of the blood vessels in their liver done before their TARE treatment as part of planning — such as CT, MRI, PET, SPECT, or DSA scans — where those images can be used to build detailed 3D maps of the liver's blood supply and how the treatment dose was distributed.
Who may not be able to join:
- People who are undergoing or have undergone TARE without sufficient imaging of the liver's blood vessels being available.
- People for whom no imaging scans — either before or after treatment — are available for the research team to review and analyse.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +32 9 3326684
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Accuracy and validation of CFD models; Identification of important procedure parameters; Uncertainty on dose to tumor/healthy tissue
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.